(Q72523055)

English

A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma

scientific article published on 01 June 1994

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8205559%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8205559%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

I G Ron

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8205559%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

Y Mordish

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8205559%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

A Eisenthal

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8205559%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

Y Skornick

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8205559%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

M J Inbar

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8205559%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

S Chaitchik

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8205559%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

publication date

1 June 1994

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8205559%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8205559%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

38

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8205559%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8205559%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

379-384

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8205559%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

https://scigraph.springernature.com/pub.10.1007/bf01517207

0 references

Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferons in the treatment of malignant melanoma. A review of recent trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of an outpatient regimen of recombinant human interleukin-2 and alpha-2a-interferon in patients with solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of carboplatin in advanced malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of metastatic malignant melanoma with 24 hours continuous venous infusion of dacarbazine and cisplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cis-dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

On the varied biologic effects of interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DTIC therapy in metastatic malignant melanoma: a simplified dose schedule

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 in cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current therapy for malignant melanoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of carboplatin in patients with metastatic malignant melanoma. A report from the Eastern Cooperative Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiorespiratory effects of immunotherapy with interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant interferon alpha-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I-II study in combination with DTIC.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of metastatic malignant melanoma with dacarbazine and cisplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/8205559

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01517207

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8205559%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8205559%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q72523055&oldid=1826251581"